Ixabepilone in metastatic breast cancer: complement or alternative to taxanes?
نویسندگان
چکیده
SCCRO (DCUN1D1) Induces Extracellular Matrix Invasion by Activating Matrix Metalloproteinase 2. Pornchai O-charoenrat, Inderpal Sarkaria, Simon G. Talbot, Pabbathi Reddy, Su Dao, Ivan Ngai, Ashok Shaha, Dennis Kraus, Jatin Shah, Valerie Rusch, Y. Ramanathan, and Bhuvanesh Singh.................................................................................................................................................6780
منابع مشابه
Ixabepilone development across the breast cancer continuum: a paradigm shift
The epothilone analog ixabepilone exhibits reduced susceptibility to several important tumor survival mechanisms that limit the efficacy of taxanes and anthracyclines. As a single agent, ixabepilone has shown promise in metastatic breast cancer when anthracyclines, taxanes, or capecitabine have failed; and in early-stage breast cancer that is taxane-naïve or has previously received taxanes in t...
متن کاملNovel combinations for the treatment of metastatic breast cancer
Anthracyclines and taxanes represent the mainstay of first-line cytotoxic therapy for metastatic breast cancer (MBC), but most patients eventually develop resistance to these agents. Consequently, alternative combinations for MBC therapy are the subject of much ongoing research. Capecitabine and ixabepilone is the only chemotherapy combination specifically approved for MBC after failure of anth...
متن کاملIxabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer.
PURPOSE The pharmacology, pharmacokinetics, clinical efficacy, safety, dosage, and administration of ixabepilone in patients with metastatic breast cancer are examined. SUMMARY The clinical utility of the three main classes of chemotherapeutic agents used in breast cancer (i.e., anthracyclines, taxanes, and fluorinated pyrimidines) is limited in some patients by the emergence of drug resistan...
متن کاملIxabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
Taxane therapy is commonly used in the treatment of metastatic breast cancer. However, most patients will eventually become refractory to these agents. Ixabepilone is a newly approved chemotherapeutic agent for the treatment of metastatic breast cancer. Although it targets microtubules similarly to docetaxel and paclitaxel, ixabepilone has activity in patients that are refractory to taxanes. Th...
متن کاملManagement of advanced breast cancer with the epothilone B analog, ixabepilone
Despite the activity of standard chemotherapies in advanced breast cancer, disease progression remains inevitable. Most patients exposed to anthracyclines and taxanes develop resistance and a significant subset shows primary resistance. The increasing use of these agents as adjuvant therapy may result in more anthracycline- and taxane-resistant patients in the metastatic setting; few treatment ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Clinical cancer research : an official journal of the American Association for Cancer Research
دوره 14 21 شماره
صفحات -
تاریخ انتشار 2008